Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study
机构:[1]Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China;[2]Lausanne Univ Hosp, Dept Oncol, Lausanne, Switzerland;[3]Univ Colorado, Div Med Oncol, Denver, CO 80202 USA;[4]Univ Calif Irvine, Sch Med, Med, Hematol Oncol,Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA;[5]Sungkyunkwan Univ, Med, Sch Med, Seoul, South Korea;[6]Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore;[7]Sun Yat Sen Univ, Med Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China;临床科室内科中山大学肿瘤防治中心[8]Seoul Natl Univ, Med Oncol, Bundang Hosp, Seongnam Si, South Korea;[9]Yonsei Univ, Yonsei Canc Ctr, Coll Med, Med Oncol, Seoul, South Korea;[10]Prince Songkla Univ, Internal Med, Hat Yai, Thailand;[11]Chulalongkorn Univ, Dept Med, Med Oncol Unit, Bangkok, Thailand;[12]Univ Hong Kong, Resp Med, Hong Kong, Hong Kong, Peoples R China;[13]Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Chaiwan, Peoples R China;[14]F Hoffmann La Roche Ltd, Med Oncol, Basel, Switzerland;[15]Roche Innovat Ctr, Clin Pharmacol, New York, NY USA;[16]Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
出处:
ISSN:
基金:
F. Hoffmann-La Roche Ltd.Hoffmann-La Roche
语种:
外文
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类|1 区医学
小类|1 区肿瘤学
最新[2023]版:
大类|1 区医学
小类|1 区肿瘤学
第一作者:
第一作者机构:[1]Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China;
推荐引用方式(GB/T 7714):
Mok T. S. K.,Peters S.,Camidge D. R.,et al.Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study[J].ANNALS OF ONCOLOGY.2017,28:191-191.
APA:
Mok, T. S. K.,Peters, S.,Camidge, D. R.,Ou, S-H I.,Ahn, J. S....&Kim, D-W..(2017).Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study.ANNALS OF ONCOLOGY,28,
MLA:
Mok, T. S. K.,et al."Alectinib (ALC) vs crizotinib (CRZ) in treatment-naive ALK plus non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study".ANNALS OF ONCOLOGY 28.(2017):191-191